Search
Hospital pharmacists and regulators lead the way on shortages
EHA welcomes initiatives but calls for more focus on causes
Medicine shortages have a negative impact on the quality and cost of treatments and on patient access to the best possible care.
SWG Committee
Current committee members
Konstanze Döhner, Germany (Chair (EHA Board member))
Dominique Bonnet, France (Vice-Chair)
Immacolata Andolfo, Italy
Igor Aurer, Croatia
Raul Cordoba, Spain
Hermann Einsele, Germany
Eleni Gavriilaki, Greece (Representative, Young EHA Committee)
Kirsten Gronbaek, Denmark (EHA Board)
Esther Oliva, Italy
Marc Raaijmakers, The Netherlands
Josef Vormoor, The Netherlands
Aim
The SWG Committee…
EHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreNew GFI1B variants in bleeding and platelet disorders
Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.
Read morePractical information
When do the meetings take place?
CRTH 2025 timeline is as follows:
Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.
EHA & ERN-EuroBloodNet Spotlight on Hypereosinophilic Syndrome Webinars
An accredited European online educational program for health professionals, organized by EHA and ERN-EuroBloodNet. DatesThe sessions will take place on :
Monday, April 15, 2024 at 17:00 (CEST). Monday, May 13, 2024 at 17:00 (CEST).
EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders
EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.
Read moreTreatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- »